GSK’s Cervarix put backfire on MSD’s Gardasil

Since the government is expected to practically include cervical cancer vaccines in the National Immunization Program(NIP) business next year, GSK and MSD Korea have exchanged words over cost-effectiveness.

GSK(GlaxoSmithKline) announced the result of ‘Cervical Cancer Vaccine’s Cost Effectiveness Analysis’ and emphasized cost-effective superiority of ‘Cervarix’ to MSD’s ‘Gardasil’ in at a meet...